Novo Nordisk has announced it will invest 432m euros in its facility in Ireland.
The tabletting facility, in Monksland, Athlone, will provide significant additional manufacturing capacity for current and future Novo Nordisk GLP-1 treatments.
The investment reinforces the company’s long-term commitment to Ireland and global healthcare innovation, providing funds for the existing facility to be upgraded and retrofitted.
The investment is a major strategic milestone for the company. It will increase the company’s manufacturing capacity for oral GLP-1s while enabling Ireland to become a critical hub in providing the treatments to markets outside the US.
Kasper Bødker Mejlvang, EVP CMC & Product Supply at Novo Nordisk said: “With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand outside the US.
“This investment, a historic milestone for Novo Nordisk in Ireland, marks our continued commitment to Ireland and our highly skilled employees in Athlone while allowing us to make a difference for millions of people living with serious chronic diseases.”
There are currently 260 employees at the plant focusing on producing high-quality oral treatments for patients, with a focus on efficiency and environmental sustainability.
Up to 500 construction jobs will be created by the project, with the site covering 45 acres (18 hectares). Construction has already begun and is expected to be completed in phases from the end of 2027 into 2028.